Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

a milestone payment from Johnson &

Johnson Pharmaceutical Research and Development, LLC (J&JPRD) triggered

by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as

a development candidate emerging from a collaboration with Sunesis.

-- Lesley A. Stolz, Ph.D., joined Sunesis in November 2007 as Vice

President, Corporate and Business Development.

Financial Highlights

-- Revenue totaled $2.0 million and $9.7 million, respectively, for the

three months and year ended December 31, 2007, compared to $2.0 million

and $13.7 million for the three months and year ended December 31,

2006. The decrease in revenue year-over-year was primarily due to

lower milestone payments from Merck & Co., Inc. in 2007 compared to

2006.

-- Research and development (R&D) expense was $8.3 million for the fourth

quarter of 2007, compared to $8.5 million for the same period in 2006.

R&D expense for the year ended December 31, 2007 totaled $36.1 million,

compared to $35.6 million in 2006. The year-over-year increase in R&D

expense was primarily due to increased clinical trial activity for SNS-

595 and preclinical program costs, partially offset by lower headcount

and lower R&D expense associated with SNS-032 and SNS-314 due to

reduced research activities in these programs.

-- General and administrative (G&A) expense for the fourth quarter of 2007

was $2.8 million, compared to $3.4 million for the fourth quarter of

2006. For the year ended December 31, 2007, G&A expense was $13.6

million, compared to $12.3 million in 2006. The quarter-over-quarter

decrease primarily resulted from lower professional services expense in

2007 compared to 2006. The year-over-year increase in G&A expense was

primarily due to increased non-cash stock-based compensation expense,
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... 15, 2014 A study has been launched ... Formula 1 track could help to tackle the problem of ... Stowhealth (a GP surgery based in Stowmarket) and academics at ... Telemetry technology, which is inspired by equipment used ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... India, April 21 /PRNewswire-Asia/ --,QIAGEN and the Chittaranjan ... establish the first large-scale cervical cancer screening,program for ... QGEN ; Frankfurt Prime,Standard: QIA) will provide ... the primary cause of cervical cancer. CNCI will ...
... Hoping that science will cast a spell on local ... team is starting a program that will harness the ... technical subjects resonate in local classrooms. , Funded by ... Foundation, the Innovations in Nanotechnology and NanoSciences initiative will ...
... Thoratec Corporation (Nasdaq: THOR ), a world ... support and restore failing hearts, said today that it ... FDA seeking to add the intended use of Destination ... ventricular assist system). The HeartMate II is a next ...
Cached Biology Technology:QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 2QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 3QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 4QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 5UH initiative will use 'Harry Potter' to conjure love for science in Houston-area schools 2UH initiative will use 'Harry Potter' to conjure love for science in Houston-area schools 3Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R) 2Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R) 3Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R) 4
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
(Date:4/17/2014)... and plant life, but there,s an invisible machine underground. ... soil, decomposing organic matter and releasing carbon into the ... in ecological systems, their identities have only now been ... genetic map of more than 10,000 species of fungi ... in the Proceedings of the National Academy of ...
(Date:4/17/2014)... of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a number ... history that most of us take for granted. At ... many spots around the globe shifted from hunting animals ... plants. , It seems so straightforward and yet the ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... shrimp-like creature at the heart of the Antarctic food ... Southern Ocean with iron stimulating the growth of ... capacity for natural storage of carbon dioxide. ... Oceanography , an international team of researchers describe how ...
... viable future biofuel especially if harvested in summer. ... could provide an important alternative to terrestrial grown biofuels; ... a seasonal basis. Harvesting the kelp in July when ... sugar release for biofuel production. , "The storage carbohydrate ...
... by women of advanced maternal age (over 35 years) ... of meiosis a critical process of chromosome duplication ... of oocytes and sperm and leading to abnormalities ... failure, pregnancy loss or, more rarely, the birth of ...
Cached Biology News:Antarctic krill help to fertilize Southern Ocean with iron 2Biofuels from the sea 2Could ovarian stimulation cause an increase in oocyte chromosome abnormalities? 2Could ovarian stimulation cause an increase in oocyte chromosome abnormalities? 3
... monoclonal antibody raised against a partial recombinant IFNA2. ... a.a.) partial recombinant protein is produced in E. ... 8 IU/ mg. OMIM: ... Lot Number: MM951100564 MA ...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Biology Products: